News stories about China Cord Blood (NYSE:CO) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. China Cord Blood earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 47.1604578398775 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

Shares of China Cord Blood (NYSE:CO) traded down $0.04 on Friday, reaching $10.22. 166,006 shares of the company’s stock were exchanged, compared to its average volume of 206,978. China Cord Blood has a twelve month low of $5.06 and a twelve month high of $14.95. The stock has a market cap of $1,237.40, a price-to-earnings ratio of 29.20 and a beta of 0.91.

China Cord Blood (NYSE:CO) last announced its quarterly earnings data on Monday, November 20th. The medical research company reported $0.09 earnings per share (EPS) for the quarter. China Cord Blood had a net margin of 26.79% and a return on equity of 9.68%. The business had revenue of $35.26 million during the quarter.

WARNING: “China Cord Blood (CO) Getting Somewhat Favorable News Coverage, Study Finds” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/02/10/china-cord-blood-co-getting-somewhat-favorable-news-coverage-study-finds.html.

China Cord Blood Company Profile

China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.

Insider Buying and Selling by Quarter for China Cord Blood (NYSE:CO)

Receive News & Ratings for China Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.